We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+29.89%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.5B
AUM Growth
+$361M
Cap. Flow
+$95.2M
Cap. Flow %
6.35%
Top 10 Hldgs %
63.32%
Holding
74
New
17
Increased
21
Reduced
30
Closed
4
Avg Time Held Equity + Options
1.4 years
Top 10 Avg Time Held Equity + Options
1.2 years
Top 20 Avg Time Held Equity + Options
1 year
Avg Time Held Equity only
1.5 years
Top 10 Avg Time Held Equity only
1.3 years
Top 20 Avg Time Held Equity only
1.1 years

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$33M
2
RVTY icon
Revvity
RVTY
+$31.9M
3
PFE icon
Pfizer
PFE
+$30.6M
4
VTRS icon
Viatris
VTRS
+$15.9M
5
INSP icon
Inspire Medical Systems
INSP
+$13.6M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$35.6M
2
IMGN icon
Immunogen Inc
IMGN
+$22.2M
3
ARGX icon
argenx
ARGX
+$12.1M
4
ILMN icon
Illumina
ILMN
+$12.1M
5
KRYS icon
Krystal Biotech
KRYS
+$8.65M

Sector Composition

Rank Sector Weight
1 Healthcare 89.26%
2 Miscellaneous 10.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
STOK icon
51
Stoke Therapeutics
STOK
$1.55B
$3.92M 0.26%
+290,000
New +$1.76M
2024 Q1
0 quarters
CRBP icon
52
Corbus Pharmaceuticals
CRBP
$82.8M
$3.49M 0.23%
+88,934
New +$2.19M
2024 Q1
0 quarters
KRYS icon
53
Krystal Biotech
KRYS
$9.56B
$3.3M 0.22%
18,557
-62,241
-77% -$8.65M
2023 Q2
3 quarters
ALEC icon
54
Alector
ALEC
$228M
$3.23M 0.22%
+536,171
New +$3.51M
2024 Q1
0 quarters
AVTR icon
55
Avantor
AVTR
$10.8B
$3.21M 0.21%
125,394
-570
-0.5% -$13.6K
2023 Q3
2 quarters
IQV icon
56
IQVIA
IQV
$44.7B
$3.08M 0.21%
12,178
-85
-0.7% -$19.8K
2020 Q4
13 quarters
MOR icon
57
DELISTED
MorphoSys AG American Depositary Shares
MOR
$3.01M 0.2%
+165,924
New +$2.45M
2024 Q1
0 quarters
VRDN icon
58
Viridian Therapeutics
VRDN
$2.2B
$2.49M 0.17%
142,075
+4,732
+3% +$91.7K
2023 Q3
2 quarters
MOH icon
59
Molina Healthcare
MOH
$11.1B
$2.39M 0.16%
5,828
-289
-5% -$112K
2023 Q2
3 quarters
XOMA icon
60
DELISTED
Xoma
XOMA
$2.33M 0.16%
97,065
+3,338
+4% +$74.8K
2022 Q3
6 quarters
IFRX icon
61
InflaRx
IFRX
$200M
$2.01M 0.13%
1,305,140
– –
2023 Q2
3 quarters
VKTX icon
62
Viking Therapeutics
VKTX
$3.41B
$1.87M 0.12%
+22,818
New +$1.02M
2024 Q1
0 quarters
TERN icon
63
DELISTED
Terns Pharmaceuticals
TERN
$1.86M 0.12%
+283,034
New +$1.85M
2024 Q1
0 quarters
JBIO icon
64
Jade Biosciences
JBIO
$839M
$1.6M 0.11%
1,547
+112
+8% +$85.5K
2022 Q4
5 quarters
CVAC icon
65
DELISTED
CureVac
CVAC
$1.56M 0.1%
515,691
+18,779
+4% +$65.9K
2023 Q2
3 quarters
RGEN icon
66
Repligen
RGEN
$11.5B
$1.51M 0.1%
8,237
-1,747
-17% -$333K
2021 Q1
12 quarters
MCRB icon
67
Seres Therapeutics
MCRB
$25.6M
$1.08M 0.07%
69,447
-18,230
-21% -$393K
2022 Q3
6 quarters
AFMD icon
68
DELISTED
Affimed
AFMD
$882K 0.06%
166,460
-1,208
-0.7% -$6.88K
2022 Q2
7 quarters
VINC icon
69
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$403K 0.03%
+3,979
New +$251K
2024 Q1
0 quarters
ACIU icon
70
AC Immune
ACIU
$240M
$369K 0.02%
124,589
– –
2021 Q3
10 quarters
A icon
71
Agilent Technologies
A
$49.6B
– –
-37,854
Closed -$5.26M –
BHVN icon
72
Biohaven
BHVN
$1.66B
– –
-66,898
Closed -$2.86M –
ILMN icon
73
Illumina
ILMN
$40B
– –
-89,039
Closed -$12.1M –
IMGN icon
74
DELISTED
Immunogen Inc
IMGN
– –
-748,950
Closed -$22.2M –
1 2
3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Eversept Partners held 74 positions worth $1.5B, up 32% from $1.14B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Eversept Partners deployed $95.2M of net new capital in Q1 2024, opening 17 new positions and adding to 21 existing holdings. Its largest new stake was Pfizer: 1,102,042 shares worth $30.6M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Natera, an estimated $35.6M trimmed.

  • Eversept Partners's largest Q1 2024 buy was Pfizer: 1,102,042 shares worth $30.6M.
  • Eversept Partners added most to GSK in Q1 2024, an estimated $33M increase.
  • Eversept Partners's biggest Q1 2024 reduction was Natera, cutting an estimated $35.6M.
  • Eversept Partners fully exited Immunogen Inc in Q1 2024, selling an estimated $22.2M.
  • Eversept Partners's ten largest holdings make up 63% of its $1.5B portfolio in Q1 2024.
  • Eversept Partners opened 17 new positions and closed 4 in Q1 2024.
  • Eversept Partners's portfolio value rose 32% quarter-over-quarter to $1.5B.

Based on Eversept Partners's 13F filing for Q1 2024, filed 15 May 2024.